We examined the ability of patient-derived human leukemic blasts to generate leukemic growth and dissemination in severe combined immunodeficiency (SCID) mice by subcutaneous inoculation without conditioning treatment or administration of growth-promoting cytokines. Additionally. we correlated the growth pattern with the clinical outcome of patients from whom the leukemic cells were derived. The leukemias displayed three distinct growth patterns, ie, either aggressive, indolent, or no tumor growth. Leukemic cells from 6 of 13 patients with acute myeloid leukemia (AML), 4 of 7 T-cell acute lymphoblastic leukemia (T-ALL), and 11 of 16 patients with B-lineage ALL grew as subcutaneous tumors, with a significant number subsequently disseminating into distant organs in SClD mice. Patients whose leukemic blasts displayed an aggressive growth and dissemination pattern in SClD mice had a relatively poor clinical UBCUTANEOUS transplantation of human solid tumor cells into immunodeficient nude mice has provided a useful model that is widely used for the study of the therapeutic efficacy of various antitumor agents. The subcutaneous growth of human hematopoietic malignancies has proved unsuccessful in this m0de1.l.~ In rare cases, leukemia cell lines will grow as a localized tumor after subcutaneous implantation but without subsequent dissemination, thus not reflecting the usual pattern of growth in Recent studies have shown the growth of some human leukemia cells in the severe combined immunodeficiency (SCID) mouse model in a manner analogous to their clinical characteristics in patients. This has allowed the propagation of human leukemic cells that in prior studies failed to adaptively grow under in vitro culture conditions or in the nude mouse model. The possible, consistent ability to propagate human leukemic cells in SCID mice may provide a new tool for studying the biologic characteristics of the various le~kemias."'~ Several investigators have shown a correlation between the ability of B-lineage acute lymphoblastic leukemia (B-lineage ALL) to grow in SCID mice and the clinical prognosis for patients from whom these samples were dekemic cells growing in SCID mice may maintain the natural characteristics of the original human primary leukemias and that the xenografted leukemia SCID mouse model may be useful for the study of the biologic behavior of leukemia cells from a given patient.
In the majority of studies conducted to date, transplantation of human leukemia was accomplished either by intravenous (IV) or intraperitoneal (P) injection of leukemic cells into SCID mice pretreated with irradiation or immunosuppresives agents. To detect leukemic engraftment, inoculated mice were killed when they exhibited clinical signs of disease (lethargy, ruffled fur, or weight loss) or 3 to 5 months after the inoculation of leukemic cells. The tissues removed from killed animals were studied by histopathologic, flow cytometric (fluorescence-activated cell sorting [FACS] [3137] [3138] [3139] [3140] [3141] [3142] [3143] [3144] [3145] [3146] outcome, whereas patients with AML and T-or B-lineage ALL whose leukemic blasts grew indolently or whose Cells failed to induce growth had a more favorable clinical course. Our study has shown that the subcutaneous inoculation of patient-derived human leukemic cells in SCID mice can engraft and grow as subcutaneous tumors with subsequent dissemination to distant organs in a manner analogous to their pattern of growth in humans. Additionally, these data suggest a clinical correlation to the growth and dissemination of some leukemic subtypes that may represent not only an additional prognosticator for patient outcome, but also a vehicle for the study of the biologic behavior of human leukemias and the development of novel therapeutic strategies. 0 1996 by The American Society of Hematology.
fluorescence in situ hybridization (FISH), or polymerase chain reaction (PCR) analysi~.~*~."*'~ However, many SCID mice that developed pathologically detectable leukemia in these studies did not exhibit obvious clinical signs of disease before autopsy. Furthermore, animals that manifested clinical signs of disease were not consistently found to have leukemic engraftment at a~t o p s y .~*~* '~~'~ Therefore, the development of an SCID mouse model in which leukemic growth might be easier to detect and follow-up and would not require the death of the animal, such as a subcutaneous tumor growth, would be helpful for the study of the correlations between the growth patterns and the clinical course and prognosis. It would also provide an important ability to examine the effect of different therapeutic strategies in the treatment of human leukemias.
Recently, we have developed an SCID mouse model that permits the subcutaneous growth of primary human acute leukemia cells and cells from the myeloid blast crisis of chronic myelogenous leukemia.l6." Furthermore, the subcutaneous growth in this model is associated with dissemina-tion of the leukemia reflecting a pattern of growth similar to the usual clinical presentation. To determine whether and to what degree different types of human leukemia would grow or disseminate within the SCID mouse model, we have subcutaneously inoculated SCID mice with primary leukemic cells derived from patients with acute myeloid leukemia (AML), T-ALL, and B-lineage ALL. In this report, we demonstrate the ability to propagate various human leukemias in an SCID mouse by subcutaneous inoculation and present the characteristics and biologic behavior of the human leukemias in this model.
MATERIALS AND METHODS

Leukemic Samples
Samples were obtained, with informed consent, during routine diagnostic blood studies or bone marrow (BM) aspirates from patients with newly diagnosed or relapsed acute leukemias at Memorial Sloan-Kettering Cancer Center (MSKCC). Thirteen AMLs, 7 TALLs, and 16 B-lineage ALLs (15 pre-B-ALLs and 1 B-ALL) were studied. Blast-enriched mononuclear cells were isolated by Ficoll Hypaque density gradient separation and washed in RPM1 1640 medium. After separation, most of the leukemic cells were freshly inoculated into SCID mice. In some patients, leukemic cells were cyropreserved in liquid nitrogen before their injection into the animal.
SCID Mice
All SCID (CB17-scidscid) mice were purchased from Taconic Farms and maintained in the MSKCC Animal Laboratory in microisolater cages under sterile conditions with a specific pathogen-free environment without the use of any antibiotics. Female SCID mice between 6 and 8 weeks of age were used.
Inoculation of Human Leukemic Cells Into SCID Mice
Approximately 1.0 to 2 X lo7 viable leukemic cells were resuspended in 100 pL of ice-cold MATRIGEL matrix (Becton Dickinson Labware, Bedford, MA) liquid and injected subcutaneously with a tuberculin syringe into the right flank of the SCID mouse. The number of SCID mice inoculated and the cell dose per mouse were dependent on the number of leukemic cells available from patient samples. The animals did not receive any conditioning treatment before inoculation. Leukemic cell growth was assessed by weekly measurements of dimensions of subcutaneous nodules. Animals were killed by cervical dislocation when the dimensions of subcutaneous nodules were greater than or equal to 1.5 cm or more than 3 months after inoculation. The gross anatomy was evaluated and samples from peripheral blood, sternum, femur, spleen, liver, lung-heart complex, kidney, brain, and tumor nodules were subsequently removed for analysis by flow cytometry (FACS), FISH, and histologic analysis. Organ weights of spleen, liver, and leukemic nodules were also measured. For secondary passage of leukemic cells, the leukemic tumor nodule was removed from SCID mice, cut into small pieces with a scalpel, and then gently ground in a 70-pm Nylon cell strainer (Becton Dickinson Labware) within a tissue culture dish containing a-minimum essential medium (a-MEM). Single-cell suspensions were collected and counted with trypan blue to determine the number of viable cells. For secondary passage of leukemia cells, a similar cell dose and method was used as for the first passage.
Analysis of Tissue From Xenografted Animals
Histopathology. Tissue sections from killed SCID mice were fixed in 10% neutral-buffered formalin, dehydrated, embedded in paraffin, sectioned, and stained according to standard histologic techniques.
Immunophenotyping. Cell suspensions derived from tissues of killed animals and primary human leukemic cells were washed in phosphate-buffered saline (PBS) and stained with directly labeled fluorescein isothiocyanate (F1TC)-conjugated and phycoerythrin (PE)-conjugated monoclonal antibodies for 30 minutes at 4°C. The cells were then washed twice and analyzed by FACS (Becton Dickinson, Mountain View, CA). The following antibodies were used for characterization of T-cell, B-cell, and myelomonocytic lineage surface markers: CD2, CD3, CD4, CD7, CD8, CD56, CDIO, CD19, CD20, HLA-DR, CD13, CD14, CD15, CD33, and CD34 (Becton Dickinson). Additionally, FACS analyses of samples of blood, BM, spleen, and liver from animals were performed by using two-color immunofluorescence staining and painvise combinations of a selected panel of antibodies (CD3-PE, CD19-PE, CD33-PE, and CD45-FITC) against human antigens and an antibody mCD45-FITC (Boehringer Mannheim, Indianapolis, IN) against a murine antigen to discern the origins of the cells.
FISH. FISH was performed as previously described.'* In brief. single-cell suspensions from tumor nodules or organs were washed and fixed in a mixture of methanol and acetic acid (3:l vol/vol). The cells were put onto slides and air-dried. Subsequently, the slides were washed at room temperature (RT) in successive jars containing 0.1 N HCI solution containing 0.5% Triton, PBS, 1% formaldehyde. PBS X 2, 2X SSC and denatured at 72°C in 70% formamide/2x SSC. Thereafter, the slides were dehydrated by 2 minutes of exposure to graded ethanol solutions at 4°C. Denatured probes (1 0 pg/ mL biotin-labeled; Oncor, Gaithersburg, MD) in a hybridization solution (Hybrisol VI; Oncor) were deposited on slides and covered with a coverslip. The slides were sealed with rubber cement, and then the hybridization took place in a moistened chamber at 37°C for 12 to 18 hours. After hybridization, the slides were washed in 65% formamide/2~ SSC at 43°C and then in 2 x SSC at 37°C and rinsed in 1 X SSC RT. Biotinylated probes for human X chromosome were detected by applying 20 pL detection reagent containing avidin/ FITC (Oncor), the plastic coverslip was added, and the slide was incubated in humidified chamber at 37°C for 30 minutes. The slides were then washed in I X SSC at RT three times and propidium iodide (2 pg/mL; Sigma, St Louis, MO) was applied for counterstain. A Zeiss fluoresence microscope (Axioskop: Carl Zeiss, Inc, Germany) was used for visualization and at least 200 cells were scored.
Long-term in vitro culture of leukemic cells. Blast-enriched mononuclear cells isolated by Ficoll Hypaque from patients-derived samples or mononuclear cells recovered from leukemic nodules were washed and plated into a-MEM medium containing 15% fetal calf serum, penicillin (100 UlmL), streptomycin ( 1 0 0 pg/mL), and 2 mmoVL L-glutamine (Sigma) at a density of 5 X 10' cells/mL and fed twice a week.
Cytogenetic andysis. Samples of cells recovered from leukemic nodules and from patients-derived tissue were examined for their karyotype by standard techniques. A minimum of 20 metaphases was examined for each sample.
Statistical Analyses
For statistical analysis, overall survival (OS) of patient was measured from the time of initial diagnosis until death from any cause or to last follow-up. Disease-free survival (DFS) was measured from the time of initiation of treatment until the time of the first relapse after complete remission (CR), death from any cause, or to the date of last follow-up if none of the preceding events had occurred. Curves of OS and DFS of the patients with the various leukemia growth patterns in SCID mice were constructed using the method of Kaplan and Meier, and statistical significance was determined with the Log-rank test and Wilcoxon test.
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New (SR) Table 1 summarizes the clinical characteristics of the 36 patients with acute leukemia evaluated in this study. The ages of patients ranged from 2 to 53 years. Patients were morphologically classified according to the French-American-British (FAB) classification into AML subtypes: M1 (3 cases), M2 (2 cases), M3 (2 cases), M4 (4 cases), and M7 (2 cases). Four patients with AML were newly diagnosed, 8 had relapsed disease, and 1 patient had a primary refractory leukemia. Of 7 patients with T-ALL, 3 were newly diagnosed, all of whom showed high-risk features (white blood cell count [WBC], >50,0OO/pL and/or age >l0 years), and 4 had leukemias that had relapsed. Of 15 patients with pre-B-ALL, 7 were newly diagnosed, 1 of whom showed highrisk features (BA13), and 8 were studied at the time of relapse. The I patient with B-ALL was in relapse.
RESULTS
Characteristics of Patients
Engrafhnent and Growth Pattern of Human AML in SCID Mice
Leukemic cells from 6 of 13 patients with AML (46.2%) were able to grow as subcutaneous nodules in SCID mice with concomitant dissemination ( (Fig 1A) . The mean times for leukemia nodule growth to reach 0.8 cm2 (diameter = 1.0 cm) and 2.0 cm2 (diameter = 1.6 cm) of surface area in mice bearing these two M4 leukemias were 9.4 2 1. I and 13.6 2 1.6 weeks after inoculation, respectively. Marked hepatosplenomegaly, axillary lymph node en- Weeks post-inoculation kemic cells from one newly diagnosed AML M7 patient (MA30) also developed a fast-growing subcutaneous tumor, and the mouse died at 13 weeks after inoculation with a 0. (Fig 1A) . The mean times for their tumors to reach to 0.8 cm2 and 2.0 cm2 surface area were 27.9 2 4.3 (n = 3) and 38.8 2 1.0 weeks (n = 2), respectively, which is remarkably longer than the tumor growth in SCID mice bearing M4 leukemia (Fig 1A) . However, splenic and/or hepatic enlargement was identified in all the SCID mice bearing tumor from patient samples MA1, MA4, and MA12. Mesenteric lymphadenopathy and dissemination of leukemia to BM, peripheral blood, spleen, liver, lung, kidney, or mediastinum was also detected by FISH, FACS, or histopathologic analysis ( Table 2) in each of the mice bearing leukemia from the 2 AML M3 patients. Dissemination of the M2 leukemia, MA1, was detected at low levels in the spleen and or liver by FACS and FISH analyses.
Of the 7 patients from whom leukemic cells did not induce subcutaneous tumors, with M4 leukemia were evaluated at diagnosis. Leukemic cells from the other 5 patients were obtained at relapse. Their original FAB subtypes were M1 (3), M2 (l), and M7 (1). None of the animals inoculated with these cells manifested significant splenic or liver enlargement or other clinical evidence of leukemic dissemination. None of the animals experienced a leukemia-related death. Human cells were detectable at levels of 1% to 4% in the liver of one mouse, in the liver and BM of another by FISH analysis (MA20 and MA34), and in the BM and spleen in another mouse (MA21) by FACS analysis. However, these readings are at the limits of the sensitivity of these techniques and are thus of uncertain significance.
Engrafrment and Growth Pattern of Human T-ALL in SCID Mice
Leukemic cells derived from 7 T-ALL patients were inoculated into SCID mice. The leukemic cells from all 4 re- For lapsed T-ALL patients (TA7, 8, 9, and 27) were able to induce rapid subcutaneous tumor growth (Fig IB) . These T-ALL leukemias displayed consistent rapid growth and widespread dissemination. Tumor-bearing mice subsequently became moribund and died soon after tumor size exceeded 2 cm2 surface area. The mean times for the tumor size to reach 0.8 cmz and 2.0 cm2 were 7.3 +. 1.0 and 9.5 ? 1.0 weeks, respectively. This was more rapid than the mean time of tumor growth of the other types of leukemias in this study (Table 3 ). An anatomic-pathologic picture characterized by axillary lymph node enlargement, hepatosplenomegaly, mediastinal lymphadenopathy, and mesenteric lymphadenopathy developed in all the SCID mice bearing relapsed T-ALL tumors. Analysis by histopathologic, FISH, and FACS analysis showed marked infiltration of leukemic cells in BM, peripheral blood, spleen, liver, kidney, lung, brain, and mediastinum (Table 2) . Leukemic cells derived from 3 newly diagnosed T-ALLs (TA16,22, and 28) who displayed high-risk features did not induce leukemic tumor growth. There was no spleen and liver enlargement or other clinical signs that indicated leukemia development and there was no evidence of leukemic cell infiltration detectable by FISH, FACS, or histopathologic analysis of the tissues.
Engrajhent and Growth Pattern of Human B-Lineage ALLs in SCID Mice
Sixteen B-lineage ALL patients were included in the study and their leukemic blast cells displayed various growth patterns. Leukemic cells derived from 5 of the 16 (31.3%; reFor personal use only. on October 3, 2017. by guest www.bloodjournal.org From (Fig IC) . The mean times to achieve a subcutaneous tumor surface area of 0.8 cm2 and 2.0 cm2 were 10.6 2.3 and 14.6 ? 3.1 weeks, respectively. All five leukemias were detected in the BM and liver by FISH and/or FACS analysis (Table 2) . Splenomegaly developed in animals bearing leukemia from 4 pre-B-ALLs and hepatomegaly, axillary, and mesenteric lymphadenopathy developed in 3 of these tumor-bearing mice. Mediastinal leukemic tumor was found in mice bearing cells from 2 patients (BA13 and 18). Leukemic cells from 3 pre-B-ALL patients (l newly diagnosed [BA31 and 2 relapsed [BA17 and 321) displayed an indolent growth pattern. Their subcutaneous leukemia tumor growth was very slow and the time to achieve a tumor surface area of 0.8 cm2 was 35.8 ? 8.7 weeks. No animals achieved a tumor size of 2.0 cm2 before being killed. Using FISH and FACS analysis, a small but significant proportion of leukemic cells (< 10%) could be detected in the liver and blood of an animal bearing leukemia BA32. Among animals bearing the other leukemias, neither histopathologic analysis nor evaluation by FISH or FACS showed leukemic cell dissemination. One mouse bearing leukemia from patient BA3b has been observed for more than 1.7 years after inoculation and the animal survives with a tumor of 2.3 cm2 surface area. Three other pre-B-ALLs inoculated into SCID mice (2 relapsed patients [BA10 and 151 and a newly diagnosed patient [BA38]) grew subcutaneous nodules during the first 1 to 2 weeks after inoculation. The growth of these subcutaneous nodules quickly plateaued. None of the animals achieved a tumor size greater than 0.2 cm2 before being killed. These animals manifested minimal or no evidence of leukemic dissemination by FACS and FISH analysis of various tissues. However, FISH and FACS analysis of the subcutaneous nodules showed a substantial proportion of the recovered cells to be of human leukemic origin.
Subcutaneous inoculated leukemic blasts from 5 patients (3 newly diagnosed [BA29, 36, and 391 and 2 relapsed [BA35 and 371) did not grow leukemic tumors or manifest evidence of leukemic dissemination.
Engraftment of the Human Leukemias in the Secondary SCID Mice Passages
To study the in vivo propagation of human leukemic cells in SCID mice, leukemic cells recovered from subcutaneous tumor tissue originally derived from 3 AMLs (MA1, 2, and 4), 3 T-ALLs (TA7,8, and 9), and 3 B-lineage ALLs (BA13, 18, and 25) were inoculated subcutaneously into secondary SCID mice at the same cell number used in the original passage. All of the leukemic clones engrafted and grew subcutaneous leukemic tumors in the secondary SCID mice and manifested the growth and dissemination patterns consistent with that observed during their original first passage in the primary SCID mice.
Cytogenetic and Phenotypic Analysis of Recovered Leukemic Cells From Mouse Tissues
Cytogenetic analysis of leukemic cells recovered from the leukemic nodules was studied in a limited number of mice and confirmed the presence of a consistent karyotype as observed in the diagnostic sample (Table 4) . Phenotypically, the leukemic cells recovered from leukemic nodules displayed the same phenotype as the original samples in the majority of specimens studied. A more mature phenotype as compared with the original cells was observed in several of the samples studied (Tables 5 , 6, and 7). 
In Vitro Growth Potential of the Leukemic Cells Derived From Patients and Recovered From Leukemic Nodules
To study the in vitro growth potential of leukemic clones, leukemic cells isolated from 30 patient-derived samples (1 2 AMLs, 6 T-ALLs, and 12 B-lineage ALLs) and 17 samples recovered from leukemic nodules (5 AMLs, 4 T-ALLs, and 8 B-lineage ALLs) were put into in vitro long-term culture, individually, without cytokine supplementation. An in vitro leukemic cell line was established from only 1 of 30 patientderived samples (relapsed TALL [TA27]). Three of 17 samples derived from leukemic nodules autonomously proliferated in vitro as leukemic cell lines. All 3 cell lines were originally derived from relapsed patients (2 T-ALLs [TA7 and 273 and 1 B-ALL [BA25]). Additionally, these three leukemias displayed an aggressive growth pattern in SCID mice ( Figure 1B and C) , suggesting a possible correlation between autonomous proliferation and an aggressive growth pattern in vivo. Because of an insufficent number of available cells, patient-derived samples from TA7 and BA25 were not initially cultured in vitro, but were first passaged in SCID mice and then cells from the nodules were cultured in vitro. Therefore, it is not clear whether the capacity of in vitro clonal generation of these human leukemic cells was promoted by the growth and passage in the SCID mice.
Correlations of Human Leukemia Growth Pattern in SCID Mice and Clinical Characteristics and Prognoses in Patients
The 2 M4 patients (MA2 and 26) whose leukemic cells displayed an aggressive growth pattern had a poor clinical outcome; 1 died 4.5 months after diagnosis without response to chemotherapy and the other died of leukemia progression after an 8-month DFS and a 20.5-month OS. In contrast, the 2 M3 patients (MA4 and 12) whose leukemic cells displayed an indolent growth pattern had a relatively favorable clinical outcome. At the time of data analysis, both of the patients were still in continuous complete remission (I in CR1 and the other in CR2) with DFSs of 5.8 and 37.7 months and OSs of 47.5 and 39.7 months, respectively. One M2 patient (MA1) whose leukemic cells displayed an indolent growth pattern also had a relatively longer DFS (24.5 months), although the patient died of leukemia 42.3 months after diagnosis. No obvious association with favorable clinical prognosis or specific AML subtype was noted in the patients whose leukemic cells did not induce tumor growth in SCID mice. The median DFS and OS of these patients was 9.3 (0.7 to 14.6) and 17.8 (11.2 to 34.4) months, respectively. Of the 7 patients, 5 relapsed within 1 year after the first complete remission was achieved and 4 died of leukemia progression approximately 1 year after diagnosis.
Four T-ALL relapsed patients whose leukemic cells grew aggressively in SCID mice had an unfavorable clinical course. Two of them (TA8 and 27) died with DFSs of 11.0 and 7.3 months, respectively. The other 2 patients (TA7 and 9) had relatively longer survivals (OS, 25.7 and 33.0 months; DFS, 16.2 and 30.2 months); however, both of them died soon after relapse. Three newly diagnosed T-ALL patients whose leukemic cells did not grow in SCID mice are still in first complete remission, with DFSs of 18.6, 15.0, and 10.1 months, respectively.
Sixteen B-lineage ALLs could also be characterized into three groups by the growth pattern of their leukemic cells in SCID mice. Five leukemias (4 pre-B-ALL and l B-ALL) had an aggressive growth pattern. Leukemic cells from 6 patients with pre B-ALL either displayed an indolent growth pattern or only developed a small subcutaneous nodule without further growth or significant dissemination in SCID mice. These were called an indolent group. Finally, 5 (pre-B-ALL) patients were classified into a no growth group based on their cells' inability to induce subcutaneous tumor growth in the SCID mice. Figure 2 shows the probability of first remission duration curves of the patients with B-lineage ALL in these three groups calculated from initial treatment after diagnosis to first relapse after achieving an initial CR. Patients whose leukemic cells, obtained either at diagnosis or at relapse and exhibiting an aggressive growth pattern, had a very poor clinical course. The median DFS and was 3.5 months (3.0 to 5.9 months) and the median OS was 7.9 months (6.0 to 18.5 months). Four of the 5 died of leukemia progression. Three of the 5 had relapsed leukemias (BA5 18, and 25) and 2 were newly diagnosed (BA13 and 31) when their cells were studied. One newly diagnosed patient died of leukemia 7.9 months after diagnosis with a DFS of 4.2 months. The other newly diagnosed patient (BA31) obtained a complete remission after induction chemotherapy, but showed increasing blast cells (8%) at a 6-month BM evaluation.
In contrast to the aggressive group, a favorable clinical outcome was found in patients both from the indolent group and the no growth group. Among 6 patients from the indolent group, only 1 patient has died of leukemia progression (at 46.7 months after diagnosis with a 41.4-month DFS). Similarly, among the 5 patients from the no growth group, only 1 has died. This patient experienced a long-term DFS (87.9 months) and OS (90.4 months).
DISCUSSION
This study has shown that the subcutaneously inoculated human leukemic cells can engraft in SCID mice and grow into subcutaneous tumors. These can subsequently disseminate to distant organs in a manner that is analogous to their pattern of growth in patients. The successful engraftment and subsequent dissemination of human leukemias in this SCID mouse model may thus provide a potentially important tool for both the study of leukemia biology and for the preclinical evaluation of novel therapeutic strategies. In addition, the growth of a measurable subcutaneous nodule that may be followed by the development of disseminated disease allows for the evaluation of therapeutic strategies involving single or multiple courses of treatment without necessitating the immediate death of the animals.
Although De Lord et al" reported an inability to achieve sustained engraftment of 17 different patient-derived samples of myeloid leukemic blasts in irradiated SCID mice after intravenous inoculation, Lapidot et a l Z o showed more successful leukemia engraftment after a pretransplantation preparative regimen (400 cGy total body irradiation) and posttransplantation use of human growth factors. In the present study, we examined the ability of human AML cells to generate leukemic growth and dissemination in SCID mice by subcutaneous inoculation without conditioning treatment or administration of growth-promoting cytokines. Leukemic cells from 6 of 13 AML patients grew into subcutaneous leukemic tumors. Furthermore, leukemic cells from 4 of 7 T-ALL and 11 of 16 B-lineage ALL patients also successfully grew into subcutaneous tumors. The majority of these tumors were associated with dissemination of leukemia, sugFor personal use only. on October 3, 2017. by guest www.bloodjournal.org From gesting that perhaps the local subcutaneous microenvirument of the SCID mouse may be more conducive to leukemic growth as compared with other routes of administration, ie, IV or IP.
We found that tumor engraftment and the pattern of leukemic cell growth and dissemination in SCID mice varied somewhat with the different types of leukemia and with different patients with the same type of leukemia. Among patients with AML, leukemic cells from 2 of 4 patients with M4 leukemia grew aggressively. These findings are consistent with previous descriptions of the relatively aggressive nature of this particular leukemic subtype in patients. In contrast, leukemic cells from 2 AML M3 patients and 1 AML M1 patient displayed an indolent growth pattern, suggesting that the different FAB subtypes may maintain their unique biologic behaviors in this animal model. These observations are consistent with those of Lapidot et al?' who previously reported that SCID mice transplanted with M4 cells showed relatively more rapid and extensive dissemination with resultant increased morbidity and mortality when compared with the animals inoculated with AML MUM2 leukemia subtypes.
Four leukemic cell samples derived from patients with relapsed T-ALL evaluated in the present study displayed a strikingly aggressive growth pattern characterized by a rapidly growing subcutaneous tumor, marked hepatosplenomegaly, lymphadenopathy, mediastinal tumor development, and severe leukemic infiltration of other organs. This pattern of growth closely correlated with the clinical manifestations in the patients from whom the samples were derived, suggesting that the transplanted cells maintained the intrinsic biologic characteristics of the original T-ALL cells.
Kamel-Reid et a l l 2 reported that leukemic cells from 5 patients with relapsed B-lineage ALL proliferated rapidly in SCID mouse organs after IV administration, whereas leukemic cells from three patients with newly diagnosed B-lineage ALL failed to engraft. We were able to show an aggressive growth pattern not only for 3 of 9 different B-lineage ALL cells derived from patients in relapse, but also for 2 of 7 Blineage ALLS from newly diagnosed patients. Pooling our data for the different leukemias, 9 of 22 (41%) relapsed or refractory leukemias (21 relapsed and 1 refractory) had an aggressive growth pattern, whereas 3 of 14 (21%) leukemias from newly diagnosed patients showed these characteristics. Of the 13 other leukemias studied at relapse, 6 (27%) exhibited indolent growth and 7 (32%) failed to grow in the SCID mice. In contrast, of the remaining leukemias studied at diagnosis, 3 (21%) exhibited indolent growth and 8 (57%) failed to grow. These results suggest that leukemic cells derived from relapsed patients may represent a subpopulation of leukemic cells that were present at diagnosis and not only have an ability to resist chemotherapy, but also have a growth advantage not intrinsic to the major population of leukemic cells derived from newly diagnosed patients.
In our subcutaneously inoculated leukemia-SCID mouse model, human primary leukemias displayed distinct growth patterns: either aggressive, indolent, or no tumor growth. Aggressive growth of AML, T-ALL, and B-lineage ALL leukemic tumors in SCID mice correlated with a poor clinical outcome in the patients from whom the leukemic cells were derived. Additionally, indolent growth of AML and Blineage ALL leukemic tumors in SCID mice correlated with a favorable outcome. No growth of patient-derived B-lineage ALLs in the SCID mice also correlated with a favorable clinical outcome. These findings are consistent with those of Uckun et al,L5,2' who reported that patients whose Blineage ALL leukemic cells did not cause histopathologically detectable leukemia had a better clinical outcome than those patients whose leukemic cells caused histopathologically detectable leukemia in their SCID mouse assay. Although the ability of leukemic cells to rapidly grow in SCID mice appears to predict for a poor clinical outcome in patients, evaluation of a larger sample size and a less heterogeneous group would be required to perform a multivariate analysis and confirms this as an independent prognostic variable. In contrast, no obvious correlation was noted in the present study between the absence of AML tumor growth in SCID mice and a good clinical outcome. This may be due to the lack of effective chemotherapy even for less aggressive AML. Finally, no indolent growth pattern of T-ALL leukemias was observed in this study. The observation period for patients from whom leukemic cells did not grow in SCID mice was too short at the time of this report to draw any definitive conclusions about correlations with clinical outcome.
Human leukemic cell growth in SCID mice derived from specimens at diagnosis may prove to be a useful predictor for the probability of relapse or long-term DFS in patients with B-lineage ALL.'5221 The finding that AML patients without tumor growth in SCID mice had a similar poor clinical outcome to those patients with an aggressive growth pattern suggests that the aggressive growth characteristic of human leukemic cells is not the only prognostic factor in the patients and that effective chemotherapy is needed even for the more indolent cases. Considering the heterogeneity of the AML patient samples used in this study, clearly a larger number of patients with the specific AML subtypes need to be studied to determine any correlations between the clinical outcome and the incidence of the different patterns of their leukemic growth in SCID mice.
Finally, our findings suggests that the SCID mouse leukemia model accurately reflects the intrinsic biologic behavior of different types of human leukemia. Moreover, these intrinsic properties are conserved after transfer of recovered leukemic cells from primary SCID mice to secondary SCID mice in the AML, T-ALL, and B-lineage ALL leukemias. This suggests the possibility of using the SCID mouse model to study the intrinsic biologic behavior of various leukemic subtypes and may allow the development of novel therapeutic strategies in the treatment of leukemias that grow aggressively.
